US/UK/Canada

Share

Contacts

  • Göran Beijer

    • Links

    Pick a time period -
    Tags ( Active)

    Dicot Pharma presents interim report Q3 2024

    Uppsala, Sweden, October 31, 2024. Dicot Pharma AB publishes its interim report for the third quarter 2024. The report is available as an attached document and on the company's website www.dicotpharma.com.Third quarter, July-September 2024 · Net sales amounts to SEK 0.0 (0.0) million · Earnings after financial items amounts to SEK -10.2 (-8.5) million · Earnings per share amounts to SEK -0.01 (-0.01) “We are encouraged by the increasing interest in our company and drug development with each new milestone passed. The most recent example is the attention we garnered at SMSNA,

    Dicot Pharma has received conditional approval for listing on Nasdaq First North Growth Market Stockholm with preliminary first day of trading November 7, 2024

    Uppsala, Sweden, October 23, 2024. Nasdaq Stockholm AB has announced that Dicot Pharma meets the listing requirements for First North Growth Market Sweden and that an application from Dicot Pharma for admission to trading will be approved. Preliminarily, the last day of trading on Spotlight will be November 6 and the first day of trading on First North will be November 7, 2024.Shares and warrants in Dicot Pharma AB will be traded with unchanged short name (DICOT) and ISIN code (SE0011178458) and (DICOT TO 6) and ISIN code (SE0022600300) respectively.  Shareholders in Dicot Pharma do not

    Dicot Pharma's results attract great attention in the US

    Uppsala, Sweden, October 22, 2024. Dicot Pharma's in-depth clinical results from the company's phase 1 study have now been presented at the US's largest conference in sexual medicine. The results regarding the improved effect on erectile function that persisted for four weeks attracted great interest among experts as no other potency drug has ever shown similar results.At a conference in Arizona organized by the Sexual Medicine Society of North America (SMSNA) over the weekend, Dicot Pharma's in-depth results from the company's phase 1 study were presented for the first time. The results

    Dicot Pharma receives approval to start Phase 2a clinical trial

    Uppsala, Sweden, October 21, 2024. Today, the pharmaceutical company Dicot Pharma was granted authorization to start its clinical phase 2a study which will be conducted in Sweden, Denmark, and the Netherlands. It is a placebo-controlled trial with the primary objective to evaluate the efficacy of the potency drug candidate LIB-01 in patients with erectile dysfunction.Dicot Pharma's second study in humans with the potency drug candidate LIB-01 has now received regulatory authorization from all relevant authorities in Sweden, Denmark, and the Netherlands. Preparations for the study are

    Nomination Committee appointed for Dicot Pharma AB

    Uppsala, Sweden, October 16, 2024. In accordance with the decision of the Annual General Meeting, a Nomination Committee has been appointed in Dicot Pharma AB. The Nomination Committee consists of Göran Beijer, Tore Robertsson and Torsten Söderberg.In accordance with the instruction for the Nomination Committee adopted by the Annual General Meeting, the members of Dicot Pharma's Nomination Committee shall be appointed by the three largest shareholders/owner groups in the company as of September 31, 2024, who wish to appoint a member. The Nomination Committee has now been appointed and

    Dicot Pharma informs that two additional patents are in the process of being approved in USA

    Uppsala, Sweden, October 14, 2024. Dicot Pharma announces today that the company has received Notice of Allowance for two US patent applications from the US Patent and Trademark Office (USPTO). These include, among other things, the active substance in LIB-01. A Notice of Allowance means that the USPTO intends to grant a patent once certain formal steps have been taken.Recently, Dicot Pharma announced that it received a Notice of Allowance from the USPTO regarding a patent application (No. 18/496,049) covering key steps in the manufacture of the active substance in LIB-01. Today, the

    Dicot Pharma receives Notice of Allowance for patent application in the US

    Uppsala, Sweden, October 11, 2024. Dicot Pharma announces today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's patent application No. 18/196,049 entitled "New compounds and methods of their manufacturing". The Notice of Allowance means that USPTO intends to grant a US patent once certain formal steps are completed.Dicot Pharma AB has received a notice from the USPTO which means that one of the company's patent applications is intended to be approved in the USA after certain formal steps are completed. Once granted, the patent will be in

    Dicot Pharma towards listing on Nasdaq First North

    Uppsala, Sweden, September 23, 2024. The pharmaceutical company Dicot Pharma AB engages FNCA Sweden AB as Certified advisor as part of the preparations for a listing on Nasdaq First North Growth Market. The listing is expected to take place in November 2024, at the same time as delisting from Spotlight Stock Market.The Board of Directors of Dicot Pharma believes that a listing on Nasdaq First North will benefit Dicot's continued development, internationalization and competitiveness. The listing applies to both Dicot Pharma's share and warrant of series TO6. All companies listed on First

    Dicot Pharma provides an operational update

    Uppsala, Sweden, September 17, 2024. Following the successful outcome of Dicot Pharma's rights issue, an operational update is being presented today. The company will continue to focus on the development of its potency drug candidate, with a phase 2a study set to commence soon. Additionally, the operational plan includes advancing R&D activities, a listing on Nasdaq First North, and initiating preclinical studies for new indications within metabolic diseases.Dicot Pharma's rights issue in August was oversubscribed, and an over-allotment option was exercised, resulting in a total of

    Dicot Pharma carries out a directed issue of units to guarantors, where 99.2 percent chose remuneration in units

    Uppsala, Sweden, September 9, 2024. Dicot Pharma AB ("Dicot Pharma") has completed the rights issue of units, consisting of shares and warrants of series 6, which was resolved by the Board of Directors on August 7, 2024 (the "Rights Issue"). In accordance with the guarantee agreements entered into and previously communicated, a directed issue of units is now being carried out to the guarantors in the Rights Issue who have chosen to receive guarantee compensation in the form of units in Dicot Pharma (the " Remuneration Issue"). Of the guarantors, 99.2 percent chose compensation in units. The

    Dicot Pharma announces last day of trading in BTU and first day of trading for warrants series TO 6

    Uppsala, Sweden, September 9, 2024. Dicot Pharma AB ("Dicot Pharma") announces that the rights issue that ended on August 27, 2024, will be registered with the Swedish Companies Registration Office this week and paid subscribed units (BTU) will be replaced with shares and warrants of series TO6. The last day of trading in BTU is September 11, 2024, and the stop date at Euroclear is September 13, 2024. The new shares and warrants series of TO 6 are expected to be booked into each shareholder's VP account/custody account on September 17, 2024. The first day of trading in warrants series of TO 6

    Dicot Pharma’s rights issue oversubscribed

    Uppsala, Sweden, September 4, 2024. Dicot Pharma AB (”Dicot Pharma”) today announces that the rights issue of units was subscribed to 124 percent, thus oversubscribed. The rights issue consists of shares and warrants of series 6 ("Units"), with preferential rights for existing shareholders (the "Rights Issue"). The outcome shows that 97,645,294 Units (approx. 95.5 percent of the Rights Issue) have been subscribed for with unit rights. In addition, Dicot Pharma received applications for subscription of a total of 29,206,360 Units without the support of unit rights (approx. 28.6 percent of the

    Dicot informs about last day for subscription of units in ongoing rights issue

    Uppsala, Sweden, August 26, 2024. Friday August 30, 2024, is the last day for subscription in Dicot Pharma's ongoing rights issue of units of approximately SEK 122.6 million (the "Rights Issue"). Please note that some banks and nominees have an earlier date for subscription deadlines. Holders of unit rights should therefore check with their bank or nominee whether they use an earlier closing date for subscription. The last day of trading in unit rights on Spotlight Stock Market is August 27, 2024.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED

    Dicot Pharma's study results selected for the largest sexual medicine conference in the US and publication in The Journal of Sexual Medicine

    Uppsala, Sweden, August 20, 2024. It is now confirmed that Dicot Pharma's in-depth clinical results will be presented at the largest conference in sexual medicine in the United States, which will be held in October 2024 in Arizona. The speaker is the American sexual medicine expert Dr Harin Padma-Nathan. The results will also be published in the scientific journal The Journal of Sexual Medicine.The company has earlier communicated, at the completion of the statistical analysis for the phase 1 clinical data, that it was decided that the results should be published through an abstract. The

    The subscription period in Dicot Pharma's rights issue begins today

    Uppsala, Sweden, August 16, 2024. The subscription period in Dicot Pharma AB's rights issue of units consisting of shares and warrants of series 6 begins today, in which the public also has the opportunity to apply interest in subscribing units. The rights issue was resolved by the Board of Directors on August 7, 2024 (the "Rights Issue").NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION

    Dicot Pharma AB publishes prospectus in connection with the upcoming rights issue

    Uppsala, Sweden, August 14, 2024. The Board of Directors of Dicot Pharma AB today publishes an EU growth prospectus (the "Prospectus") in relation to the rights issue of units consisting of shares and warrants of series TO6 resolved by the Board of Directors on August 7, 2024 (the "Rights Issue"). The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH

    Dicot Pharma AB presents interim report Q2 2024

    Press release: Uppsala, Sweden, August 9, 2024. Dicot Pharma AB (publ) publishes its interim report for the second quarter 2024. The report is available as an attached document and on the company's website www.dicotpharma.com.Second quarter, April-June 2024 · Net sales amounts to KSEK 0 (0) · Earnings after financial items amounts to KSEK -13,144 (-10,050) · Earnings per share amounts to SEK -0.02 (-0.02) “April began with the exciting news that our first clinical study shows consistently positive results. The safety profile, which was the main focus of the study, is of the

    The board of directors of Dicot Pharma has resolved on a rights issue of approximately SEK 122.6 million

    Uppsala, Sweden, August 7, 2024. The Board of Directors of Dicot Pharma AB ("Dicot" or the "Company") announced on June 30, 2024, its intention to resolve on a rights issue, consisting of shares and warrants ("Units"), of approximately SEK 125 million. With the support of authorization from the Extraordinary General Meeting on August 1, 2024, the Board of Directors of Dicot has today resolved on an issue of Units of approximately SEK 122.6 million with preferential rights for the Company's existing shareholders (the "Rights Issue"). The subscription price has been set at SEK 1.20 per Unit,

    Dicot Pharma has submitted clinical trial application for phase 2a trial

    Uppsala, Sweden, July 8, 2024. Dicot Pharma announces today that a clinical trial application for a phase 2a trial with the drug candidate LIB-01, has been submitted. The trial is planned to start in the fourth quarter of 2024 as previously communicated. The trial is fully funded with the amount secured in advance in the announced rights issue that the company intends to carry out in August.Dicot is developing a new potency drug with the aim to treat erectile dysfunction better than existing drugs on the market. With good results from the company's recently completed phase 1 trial, a

    Dicot Pharma has successfully completed a pre-IND meeting with FDA

    Uppsala, Sweden, July 2, 2024. Dicot Pharma AB today announced that the company has held a pre-IND meeting with the US Food and Drug Administration (FDA) and received positive feedback on the development program for the drug candidate LIB-01. This is considered a validation of the quality of the program and is an important step towards an application to include US study centers in future clinical studies and to ensure that the current development plan meets the regulatory requirements for future market approval in the US.Dicot Pharma has recently had its first formal interaction with the US

    Clarification: The board of directors of Dicot Pharma intends to resolve on a rights issue of approximately SEK 125 million

    Dicot Pharma AB makes a clarification to the press release published on June 30, 2024, at 17:28. The clarification is made to prevent a new interpretation of how to communicate information on the subscription price discount. The discount in the rights issue will indicatively amount to approximately 30 percent in relation to the theoretical ex-rights price. The information is included in this press release. Otherwise, the press release remains unchanged. Uppsala, Sweden, July 1, 2024. The Board of Directors of Dicot Pharma AB ("Dicot" or the "Company") announces its intention to resolve on

    The board of directors of Dicot Pharma intends to resolve on a rights issue of approximately SEK 125 million

    Uppsala, Sweden, June 30, 2024. The Board of Directors of Dicot Pharma AB ("Dicot" or the "Company") announces its intention to resolve on a rights issue of units consisting of shares and warrants (“Units”) equivalent to approximately SEK 125 million before deductions for transaction costs (the "Rights Issue"). In addition, the Company can receive additional proceeds from the warrants issued as part of the Units. The Board of Directors intends to publish a notice to an extraordinary general meeting (the "EGM") planned to be held on August 1, 2024, to authorize the Board of Directors to

    Experts from Dicot Pharma's clinical study behind submitted abstract

    Uppsala, Sweden, June 18, 2024. The statistical analysis of Dicot Pharma's phase 1 data is now completed, reinforcing and deepening the results the company communicated in April after the end of the study. The results of the analysis will be published in an abstract submitted to North America's largest conference in the field and featuring some of the most prominent names within sexual medicine as co-authors.Dicot Pharma's statistical analysis of the Phase 1 study is completed. The analysis reinforces and deepens the results that were communicated instantly after the end of the study in

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe